April 2025 – Page 10

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

2 months ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development

Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

2 months ago talkbio0Tagged Amlitelimab, Asthma, Immunology, Kymab, sanofi

Asthma, Amlitelimab, Kymab, sanofi, Immunology

Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn

2 months ago talkbio0Tagged Acquisitions, adaptation, Artificial Intelligence, biotech downturn, growth opportunities, innovation, Landscapes, layoff, Precision Medicine, regulatory, strategic, Survival, trends qualifier

biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities

Sanofi backs $90M financing for I&I biologic developer

2 months ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

J&J brushes off tariff headwinds with raised forecast, oncology surge

2 months ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

2 months ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

2 months ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market